BioSpaceOriginal article
Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study
Phase 2positivePemvidutidePositive
AI Analysis
Summary
Altimmune's pemvidutide demonstrated a highly statistically significant treatment effect in a mid-stage study of alcohol use disorder patients. The company faces competition from Eli Lilly and Baseline Therapeutics in the GLP-1/GIP agonist space for this indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Pemvidutide showed highly statistically significant treatment effect in patients with alcohol use disorder
Importance:7/10
Sentiment:
0.85
GLP-1/GIP agonistalcohol use disordermid-stage trialpositive datacompetitive landscape
Related Companies
Read the original article
Published by BioSpace on July 28, 2026 12:54 PM